Research
Hormonal
GLP-1 receptor agonists (Liraglutide, Semaglutide) and Tirzepatide reduce food intake primarily by increasing satiety and reducing neural activation in brain areas associated with appetite and reward, rather than just delaying gastric emptying.
Semaglutide (2.4 mg weekly) works by acting on your brain to make you feel full sooner and reducing the desire for high-calorie foods. It is not just about stomach emptying. Start with a low dose to minimize side effects, titrating up to 2.4 mg over several months.
StrongSupportsVERY_HIGH confidence
Semaglutide also induces central c-Fos activation in secondary brain areas without direct GLP-1R interaction... having direct and indirect effects on neutral pathways involved in homeostatic (appetite, hunger, satiety) and hedonic (food preference, cravings, control of eating) aspects of food intake and reward-related behaviours pertaining to food [39]. Conversely, only a very small percentage of weight loss is explained by delayed gastric emptying and gastrointestinal side effects (nausea or vomiting) [40].
Why this rating
Supported by multiple phase-3 trials (STEP, SCALE) and mechanistic studies.
Source
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Valeria Guglielmi et al. · Current Obesity Reports · 2023
narrative_reviewCited 31×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →